Quote:

---

and our own trial design/ inexperience (mixture of severe and critical in one trial, age distribution, ...).

---

I'm sure the choice for severe/critical was an effort to get the trials filled faster. Can you imagine how long it would have took for 300+ critical. If it weren't for the two doses and the use of dexamethasone (which wasn't in use when the trial was designed) it wouldn't have been a problem. With age distribution doing a breakout by age in a small trial would have been meaningless when it came to an approval. The skew towards leronlimab in over 65s was extremely unlikely to be due to chance so that wasn't a flaw in protocol design but in implementation. Thanks Amarex!